

**EUROPEAN
CURRICULUM VITAE
FORMAT**



PERSONAL INFORMATION

Name	BALDI GIACOMO GIULIO
Address	VIA SUOR NICCOLINA 20, 59100 PRATO
Telephone	+39 0574 802525
Fax	+39 0574 802903
E-mail	giacomogiulio.baldi@uslcentro.toscana.it
Nationality	Italian
Date of birth	08.05.1980

WORK EXPERIENCE

- Dates (from – to) May 2012 - to present
- Name and address of employer Hospital of Prato - 59100, Prato, Italy
 - Type of business or sector “Sandro Pitigliani” Medical Oncology Unit - Department of Oncology
 - Occupation or position held Medical Consultant of the Medical Oncology Unit, from May 2012 to present.
- Dates (from – to) November 2018 – June 2019
- Name and address of employer Fondazione IRCCS, Istituto Nazionale dei Tumori – 20133, Milan, Italy
 - Type of business or sector Medical Oncology Division 2 – Mesenchymal Tumor Unit (director: Prof. Paolo G Casali)
 - Occupation or position held Medical Consultant
- Dates (from – to) November 2009 – October 2011
- Name and address of employer Medical Oncology Department – University of Pisa, Pisa, Italy
 - Type of business or sector Medical Oncology Division (director: Prof. Alfredo Falcone)
 - Occupation or position held Senior staff member
- Dates (from – to) November 2011 – May 2012
- Name and address of employer Fondazione IRCCS, Istituto Nazionale dei Tumori – 20133, Milan, Italy
 - Type of business or sector Medical Oncology Department - Mesenchymal Tumor Unit (director: Prof. Paolo G Casali)
 - Occupation or position held Visiting physician from November 2011 to December 2011
Attending physician from January 2012 to May 2012
- Dates (from – to) Currently
- Name and address of employer/• Member of the European Society of Medical Oncology (ESMO)
Type of business or sector
- Dates (from – to) Currently
- Name and address of employer/• Member of Connective Tissue Oncology Society (CTOS)
Type of business or sector

Type of business or sector

- Dates (from – to) Currently
- Name and address of employer/
Type of business or sector Member of Associazione Italiana Oncologia Medica (AIOM)
- Dates (from – to) Currently
- Name and address of employer/
Type of business or sector Member of Italian Sarcoma Group (ISG)

EDUCATION AND TRAINING

- Dates (from – to) September 2006 – October 2009
- Name and type of organisation providing education and training University of Pisa, Italy
 - Title of qualification awarded Post-graduate Diploma in Medical Oncology
 - Level in national classification 30/30 cum laude (if appropriate)
- Dates (from – to) February 2006
- Name and type of organisation providing education and training University of Florence, Italy
 - Title of qualification awarded National license in Medicine and Surgery
- Dates (from – to) November 1999-July 2005
- Name and type of organisation providing education and training University of Florence, Italy
 - Title of qualification awarded Degree in Medicine and Surgery
 - Level in national classification 110 /110 cum laude. Final thesis: "Lymph node biopsy in breast carcinoma: detection rate with lymphoscintigraphy plus coloring agent"
- Dates (from – to) July 1999
- Name and type of organisation providing education and training Liceo Classico "N.Forteguerra", Pistoia, Italy
 - Title of qualification awarded High School Diploma
 - Level in national classification 100/100 (if appropriate)

Visiting physician

- Dates (from – to) November 2011 – December 2011
- Name and type of organisation providing education and training Medical Oncology Department - Mesenchymal Tumor Unit (director: Prof. Paolo G Casali)

PERSONAL SKILLS AND COMPETENCES

*Acquired in the course of life and career
but not necessarily covered by formal
certificates and diplomas.*

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES

- Reading skills
- Writing skills
- Verbal skills

ENGLISH

excellent
good
good

CLINICAL TRIAL EXPERIENCE

*(As principal investigator or
co-investigator)*

- 1) A Double-Blind, Randomized, Placebo-Controlled, phase II study of Enzastaurin with 5 FU/LV plus bevacizumab as maintenance regimen following first line therapy for metastatic colorectal cancer
- 2) A Phase II/III study of Mk-0646 treatment in combination with cetuximab and irinotecan for patients with metastatic colorectal cancer.
- 3) Adjuvant treatment of fully resected stage III colon cancer with FOLFOX-4 versus FOLFOX-4 plus cetuximab (PETACC-8)
- 4) A randomized trial investigating the role of FOLFOX-4 regimen duration (3 vs 6 months) and bevacizumab as adjuvant therapy for patients with stage II/III colorectal cancer (TOSCA Study)
- 5) A randomized, three arm multinational phase III study to investigate bevacizumab (q3w or q2w) in combination with either intermittent capecitabine plus oxaliplatin (XELOX q3w) or fluorouracil/leucovorin with oxaliplatin (FOLFOX-4) versus FOLFOX-4 regimen alone as adjuvant chemotherapy in colon carcinoma
- 6) An open label randomized phase III study of intermittent oral capecitabine in combination with intravenous oxaliplatin (q3w, "XELOX") versus fluorouracil-leucovorin as adjuvant therapy for patients who have undergone surgery for colon carcinoma. AJCC/UICC stage III (Dukes stage C)
- 7) Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
- 8) The TEAM trial: A randomized phase III, open label, multicentric, two arm study to compare the efficacy of Tassigna versus dacarbazine (DTIC) in the treatment of patients with metastatic and/or inoperable melanoma harboring a c-Kit mutation
- 9) A double blind, randomized, placebo-controlled, phase III study to assess the efficacy of recMAGE-A3 + AS15 ASC1 as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma.
- 10) An Open-Label, multicenter, phase III trial of ABI-007 vs dacarbazine in previously untreated patients with metastatic malignant melanoma
- 11) An open label, single arm, phase II study of combination RAD-001 and octreotide LAR in patients with advanced neuroendocrine tumors as first line treatment
- 12) European Expanded Access Programme of ipilimumab in patients with pre-treated advanced melanoma.
- 13) A Phase III randomized open-label study comparing GSK1120212 to chemotherapy in patients with advanced or metastatic BRAF V600E/K mutation-positive melanoma
- 14) An open label, multicenter, expanded access study of RO5185426 in patients with metastatic melanoma
- 15) A Phase III Randomized trial of FOLFOXIRI + Bevacizumab versus FOLFIRI + Bevacizumab as first line treatment for metastatic colorectal cancer (TRIBE Study)
- 16) An open label multicenter randomized phase III study of second line chemotherapy with or without bevacizumab in metastatic colorectal cancer patients who have received first line chemotherapy plus bevacizumab (BEBYP Study)
- 17) Cetuximab e irinotecan in pazienti affetti da carcinoma coloretale metastatico selezionati in base allo stto mutazionale di KRAS e alla variante allelica di EGFR introne 1CA tandem repeats: studio prospettico di fase II e analisi retrospettiva di nuovi potenziali fattori predittivi (Studio RAS&RASH)
- 18) Open label multi center phase II study of FOLFOXIRI in combination plus bevacizumab in patients with metastatic colorectal cancer (FOIB study)
- 19) A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
- 20) A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
- 21) A phase II-III, multicenter, randomized, double-blind study of selinexor (KPT-330) versus

- placebo in patients with advanced unresectable dedifferentiated liposarcoma
- 22) A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
 - 23) Safety and efficacy of trabectedin as first line in advanced soft tissue sarcoma (STS) patients unfit to receive standard chemotherapy: a prospective phase II study with clinical and molecular correlates
 - 24) Epithelioid Sarcoma. An Observational Study
 - 25) A non-interventional, multi center, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma (STS)
 - 26) Retrospective chart review of patients participating in the pazopanib sarcoma named patient programme. The SPYRE study
 - 27) Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients
 - 28) Metronomic Cyclophosphamide vs Doxorubicin in Elderly Patients With Advanced Soft Tissue Sarcomas. Randomized, Controlled, Open Label Clinical Trial
 - 29) A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

ANNEXES Scientific manuscripts

19 June 2021

Giacomo G Baldi

Giacomo Giulio Baldi

<https://orcid.org/0000-0003-0798-7752>

Prodotti (36 of 36)

In Reply

The Oncologist

2020-12-12 | journal-article

DOI: 10.1002/ONCO.13518

Sorgente:Crossref

The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis

The Oncologist

2020-11-12 | journal-article

DOI: 10.1634/theoncologist.2020-0352

Sorgente:Crossref

Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case-series analysis within the Italian Rare Cancer Network.

Cancer

2020-10 | journal-article

PMID: 33107985

DOI: 10.1002/cncr.33247

Sorgente:Giacomo Giulio Baldi via Europe PubMed Central

Extraskeletal Myxoid Chondrosarcoma: State of the Art and Current Research on Biology and Clinical Management

Cancers

2020-09-21 | journal-article

DOI: 10.3390/cancers12092703

Sorgente:Crossref

Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group.

Cancer

2020-08 | journal-article

PMID: 32749681

DOI: 10.1002/cncr.33120

Sorgente: Giacomo Giulio Baldi *via* Europe PubMed Central

The natural history of epithelioid sarcoma. A retrospective multicentre case-series within the Italian Sarcoma Group

European Journal of Surgical Oncology

2020-07 | journal-article

DOI: 10.1016/j.ejso.2020.03.215

Sorgente: Crossref

Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.

Expert review of clinical pharmacology

2020-06 | journal-article

PMID: 32478598

DOI: 10.1080/17512433.2020.1771179

Sorgente: Giacomo Giulio Baldi *via* Europe PubMed Central

Dedifferentiated soft tissue leiomyosarcoma with heterologous osteosarcoma component: case report and review of the literature.

Clinical sarcoma research

2020-04 | journal-article

PMID: 32280451

PMC: PMC7133003

DOI: 10.1186/s13569-020-00129-5

Sorgente: Giacomo Giulio Baldi *via* Europe PubMed Central

Clinical features, prognostic factors and outcome in a series of 29 extra-skeletal Ewing Sarcoma. Adequate margins and surgery-radiotherapy association improve overall survival.

Journal of orthopaedics

2020-03 | journal-article

PMID: 32273664

DOI: 10.1016/j.jor.2020.03.018

Sorgente:Giacomo Giulio BaldiviaEurope PubMed Central

Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.

Cancer

2019-09 | journal-article

PMID: 31536651

DOI: 10.1002/cncr.32508

Sorgente:Giacomo Giulio BaldiviaEurope PubMed Central

Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments.

Expert opinion on pharmacotherapy

2019-05 | journal-article

PMID: 31136210

DOI: 10.1080/14656566.2019.1618271

Sorgente:Giacomo Giulio BaldiviaEurope PubMed Central

Leiomyosarcoma: Clinicopathological study and retrospective analysis of prognostic factors in a series of 100 patients.

Journal of orthopaedics

2019-03 | journal-article

PMID: 30976144

PMC: PMC6441716

DOI: 10.1016/j.jor.2019.03.004

Sorgente:Giacomo Giulio BaldiviaEurope PubMed Central

Soft tissue sarcoma in Italy: From epidemiological data to clinical networking to improve patient care and outcomes.

Cancer epidemiology

2019-03 | journal-article

PMID: 30870746

DOI: 10.1016/j.canep.2019.02.012

Sorgente: Giacomo Giulio Baldi via Europe PubMed Central

Standard treatment and emerging drugs for managing synovial sarcoma: adult's and pediatric oncologist perspective.

Expert opinion on emerging drugs

2019-03 | journal-article

PMID: 30841761

DOI: 10.1080/14728214.2019.1591367

Sorgente: Giacomo Giulio Baldi via Europe PubMed Central

Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?

Clinical orthopaedics and related research

2018-09 | journal-article

PMID: 30778015

PMC: PMC6259811

DOI: 10.1007/s11999.0000000000000104

Sorgente: Giacomo Giulio Baldi via Europe PubMed Central

Liposarcoma: Clinico-pathological analysis, prognostic factors and survival in a series of 307 patients treated at a single institution.

Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association

2018-07 | journal-article

PMID: 30007495

DOI: 10.1016/j.jos.2018.06.008

Sorgente: Giacomo Giulio Baldi via Europe PubMed Central

Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

2018-03 | journal-article

PMID: 29650420

DOI: 10.1016/j.ejso.2018.03.020

Sorgente: Giacomo Giulio Baldi via Europe PubMed Central

Different View on Larynx Preservation Evidence-Based Treatment Recommendations.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

2018-03 | journal-article

PMID: 29558275

DOI: 10.1200/jco.2018.77.8001

Sorgente: Giacomo Giulio Baldi via Europe PubMed Central

Complete response after rechallenge with trabectedin in a patient with previously responding high-grade undifferentiated sarcoma.

Anti-cancer drugs

2016-10 | journal-article

PMID: 27348763

PMC: PMC5010279

DOI: 10.1097/cad.0000000000000398

Sorgente: Giacomo Giulio Baldi via Europe PubMed Central

Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone.

Clinical sarcoma research

2016-09 | journal-article

PMID: 27651889

PMC: PMC5022265

DOI: 10.1186/s13569-016-0056-0

Sorgente: Giacomo Giulio Baldi via Europe PubMed Central

Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis.*European journal of cancer (Oxford, England : 1990)*

2015-11 | journal-article

PMID: 26602014

DOI: 10.1016/j.ejca.2015.08.026

Sorgente: Giacomo Giulio Baldi via Europe PubMed Central**Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.***Journal of clinical pathology*

2015-09 | journal-article

PMID: 26338802

DOI: 10.1136/jclinpath-2015-203248

Sorgente: Giacomo Giulio Baldi via Europe PubMed Central**Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network.***Anti-cancer drugs*

2015-07 | journal-article

PMID: 25763543

PMC: PMC4730787

DOI: 10.1097/cad.0000000000000228

Sorgente: Giacomo Giulio Baldi via Europe PubMed Central**Small-bowel neuroendocrine tumor and retroperitoneal fibrosis: efficacy of octreotide and tamoxifen.***Tumori*

2015-03 | journal-article

PMID: 25702678

DOI: 10.5301/tj.5000259

Sorgente: Giacomo Giulio Baldi via Europe PubMed Central**Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.***European journal of cancer (Oxford, England : 1990)*

2014-09 | journal-article

PMID: 25269954

DOI: 10.1016/j.ejca.2014.09.004

Sorgente: Giacomo Giulio Baldi via Europe PubMed Central

Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options.

Clinical sarcoma research

2013-04 | journal-article

PMID: 23594799

PMC: PMC3637638

DOI: 10.1186/2045-3329-3-6

Sorgente: Giacomo Giulio Baldi *via* Europe PubMed Central

Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients.

Clinical sarcoma research

2013-04 | journal-article

PMID: 23551825

PMC: PMC3637255

DOI: 10.1186/2045-3329-3-4

Sorgente: Giacomo Giulio Baldi *via* Europe PubMed Central

Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.

Clinical colorectal cancer

2011-09 | journal-article

PMID: 21903485

DOI: 10.1016/j.clcc.2011.06.013

Sorgente: Giacomo Giulio Baldi *via* Europe PubMed Central

Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC).

Current cancer drug targets

2011-01 | journal-article

PMID: 20578980

DOI: 10.2174/156800911793743600

Sorgente: Giacomo Giulio Baldi *via* Europe PubMed Central

Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.

Journal of the National Cancer Institute

2010-12 | journal-article

PMID: 21123833

DOI: 10.1093/jnci/djq456

Sorgente: Giacomo Giulio Baldi *via* Europe PubMed Central

Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.

Critical reviews in oncology/hematology

2010-07 | journal-article

PMID: 20619672

DOI: 10.1016/j.critrevonc.2010.06.003

Sorgente: Giacomo Giulio Baldi *via* Europe PubMed Central

Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine.

Nature reviews. Clinical oncology

2009-11 | journal-article

PMID: 19861994

DOI: 10.1038/nrclinonc.2009.148

Sorgente: Giacomo Giulio Baldi *via* Europe PubMed Central

Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients.

Expert opinion on biological therapy

2009-08 | journal-article

PMID: 19534585

DOI: 10.1517/14712590903081694

Sorgente: Giacomo Giulio Baldi *via* Europe PubMed Central

Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.

Annals of surgery

2009-03 | journal-article

PMID: 19247029

DOI: 10.1097/sla.0b013e31819a0486

Sorgente: Giacomo Giulio Baldi *via* Europe PubMed Central

High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.

The oncologist

2008-12 | journal-article

PMID: 19056857

DOI: 10.1634/theoncologist.2008-0181

Sorgente: Giacomo Giulio Baldi *via* Europe PubMed Central

Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy.

British journal of cancer

2008-08 | journal-article

PMID: 18728661

PMC: PMC2528158

DOI: 10.1038/sj.bjc.6604555

Sorgente: Giacomo Giulio Baldi *via* Europe PubMed Central

Ultima modifica record 23-feb-2021 14.41.01